-
-
Call more information
660-596-2224 -
ASA Monitor April 2024, Vol. 88, 14. AI digital biomarker for lung fibrosis diagnosis Imvaria Inc. has gained FDA approval for Fibresolve, an AI-driven digital biomarker solution facilitating noninvasive diagnosis of lung fibrosis, notably idiopathic pulmonary fibrosis (IPF). Lung fibrosis is a life-threatening disease, with IPF being particularly devastating. Current therapies are expensive and potentially toxic […]
Read MoreAuthor: Patsy Newitt Becker’s ASC Review ASCs are facing major obstacles to securing anesthesia coverage, and the decline in reimbursements is exacerbating the issue. Here are six notes about the decline of reimbursements: 1. The average anesthesia reimbursement rate for 2023 was $21.88, a 5.5% decline from 2019, according to a Jan. 16 blog post from Coronis […]
Read MoreAuthor: Jennifer R. Root, MD, FASA ASA Monitor April 2024, Vol. 88, 32. For most of my career, when I have seen something unusual (like a sneeze under a general anesthetic – I’ve seen it twice now), the only people to discuss it with are your partners. And unless you are in an academic environment, that […]
Read MoreAuthor: Patsy Newitt Becker’s ASC Review Raynaldo Ortiz Jr., MD, an anesthesiologist who allegedly injected heart-stopping drugs into IV bags at Baylor Scott & White Surgicare North Dallas, appeared in court ahead of his trial, which is set to begin April 1, according to ABC affiliate WFAA. Dr. Ortiz has been in federal custody since his […]
Read MoreASA Monitor April 2024, Vol. 88, 14. “GO chip” for monitoring cancer treatment A study from the University of Michigan introduces a chip for processing blood samples to monitor cancer cells, providing an early assessment of efficacy by the fourth week of treatment. The technology aims to reduce the delay in evaluating cancer treatments, enabling timely […]
Read More